Proceedings of the National Academy of Sciences · 2008 · 82 citations · 29 references
PharmacyMedicinal ChemistryMolecular BiologyDrug DesignDrug DiscoveryMolecular RecognitionLigand BindingMacromolecular AssemblyMultivalent InteractionsProtein-ligand BindingReceptor-ligand InteractionsSupramolecular PolymersBinding Affinity EnhancementMultivalent InhibitorsMultivalent Ligand BindingMultivalent LigandsMultivalent RecognitionReceptorsTarget-ligand InteractionsTransgenic Mice
We demonstrate that interactions between multimeric receptors and multivalent ligands are dramatically enhanced by recruiting a complementary templating receptor such as an endogenous multimeric protein but only when individual ligands are attached to a polymer as preorganized, covalent, heterobifunctional pairs. This effect cannot be replicated by a multivalent ligand if the same recognition elements are independently arrayed on the scaffold. Application of this principle offers an approach to create high-avidity inhibitors for multimeric receptors. Judicious selection of the ligand that engages the templating protein allows appropriate effector function to be incorporated in the polymeric construct, thereby providing an opportunity for therapeutic applications. The power of this approach is exemplified by the design of exceptionally potent Escherichia coli Shiga toxin antagonists that protect transgenic mice that constitutively express a human pentraxin, serum amyloid P component.
29
Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands
Pavel I. Kitov, Joanna Sadowska, George L. Mulvey et al. · Nature · 2000 · 864 citations
Multivalency and Cooperativity in Supramolecular Chemistry
Jovica D. Badjić, Alshakim Nelson, Stuart Cantrill et al. · Accounts of Chemical Research · 2005 · 632 citations
Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis
Mark B. Pepys, J. Herbert, W. L. Hutchinson et al. · Nature · 2002 · 545 citations